Atractylone

Other Names

(4ALPHAS,8ALPHAR)-3,8ALPHA-DIMETHYL-5-METHYLENE-4,4ALPHA,5,6,7,8,8ALPHA,9-OCTAHYDRONAPHTHO[2,3-B]FURAN(4aS,8aR)-3,8a-Dimethyl-5-methylen-4,4a,5,6,7,8,8a,9-octahydronaphtho[2,3-b]furan(4aS,8aR)-3,8a-Dimethyl-5-methylene-4,4a,5,6,7,8,8a,9-octahydronaphtho[2,3-b]furan(4aS,8aR)-3,8a-Diméthyl-5-méthylène-4,4a,5,6,7,8,8a,9-octahydronaphto[2,3-b]furane(4aS,8aR)-3,8a-Dimethyl-5-methylene-4,4a,6,7,8,9-hexahydrobenzo[f]benzofuran(4aS,8aR)-3,8a-dimethyl-5-methylidene-4,4a,5,6,7,8,8a,9-octahydronaphtho[2,3-b]furanAtractylonNaphtho[2,3-b]furan, 4,4a,5,6,7,8,8a,9-octahydro-3,8a-dimethyl-5-methylene-, (4aS,8aR)-苍术酮

Synopsis

Atractylone (Atractylon): A Comprehensive Reference

1. Identity and Chemical Profile

Names and Classification

Atractylone is a sesquiterpene that is most frequently found in the Asteraceae family, with its richest source in the rhizomes of some species mainly from the genus Atractylodes. The compound is also rendered in the literature as atractylon — both spellings refer to the same molecule, and the two names are used interchangeably across peer-reviewed publications. Its CAS registry number is 6989-21-5, its molecular formula is C₁₅H₂₀O, and its molecular weight is 216.324 g/mol; it is classified as a sesquiterpenoid.

Atractylone is a sesquiterpene compound mainly extracted from Rhizoma Atractylodis and is one of the main active components in the volatile oil, accounting for up to 26.3% of the essential oil. Structurally, it belongs to the eucalyptane-type sesquiterpenes, a subgroup characterised by a furan-containing bicyclic skeleton. The presence of double bonds in the skeleton of atractylone reduces its stability, making it unstable at room temperature and prone to self-oxidation under sunlight; the resulting decrease in effective content greatly weakens its biological efficacy, making stability and maintenance of effective concentration an urgent research challenge.

Natural Sources

Atractylone is most frequently found in the Asteraceae family, with its richest source in the rhizomes of species from the genus Atractylodes, whose members occur mostly in parts of China, Korea, Japan, India, and Thailand. The primary source species include:

Atractylodes macrocephala Koidz. — known as "Bai Zhu" (白術) in Traditional Chinese Medicine (TCM); the rhizome of this perennial herb is among the most widely used. It is a drug commonly used in traditional Chinese medicine and has been used as a food and medicinal herb in China for thousands of years; in China, it is mainly distributed in Zhejiang Province and is known as one of the authentic medicinal herbs "Zhebawei."
Atractylodes lancea and Atractylodes chinensis — known collectively as "Cang Zhu" in TCM, these species are also important sources of atractylone, typically in their volatile oil fractions. Related species, A. lancea and A. chinensis, both called black or gray atractylodes, are also used medicinally for similar but distinct purposes.

Major chemical constituents of the Atractylodes rhizome include atractylone, atractylol, butenolide B, acetoxyatractylon, hydroxyatractylon, and vitamin A. Within the rhizome's essential oil, atractylone co-occurs with other sesquiterpenes including atractylenolides I, II, and III, hinesol, and β-eudesmol. The common sesquiterpenes found in A. macrocephala include atractylenolide, atractylon, AT-I, AT-II, AT-III, AT-IV, diacetyl-atractylodinolide, AT-V, AT-VI, AT-VII, 3β-acetoxyatractylenolide, dehydroatractylonolide, isoatractyloside A, atractylodinamide, and 8β-methoxy-atractylenolide II.

Common Forms and Preparations

Atractylone is encountered in both traditional and research settings in several distinct forms:

Crude dried rhizome decoction: The standard dose of the crude rhizome material in TCM practice is 3–10 g as a decoction (strong tea) or 1–4 ml of tincture; doses of dried material are 3–12 g.
Processed (stir-fried) rhizome: Thermally processed rhizomes of Atractylodes macrocephala have a long history of use in TCM for treating various disorders and have been an integral part of various traditional drugs and healthcare products; in TCM, herbal medicines are in most cases uniquely processed, as it is thought that processing can alter the properties of herbal medicines to achieve desired functions, increase potency, and/or reduce side effects. A common preparation involves stir-frying the rhizome with wheat bran.
Isolated essential oil: Atractylone can be concentrated via steam distillation or solvent extraction of the rhizome to yield an essential oil fraction enriched in sesquiterpenes.
Purified isolate (research grade): Highly purified atractylone (95–99% purity) is produced for laboratory research by HPLC-directed isolation, and its structure is confirmed by mass spectrometry and NMR. The compound is available for research purposes in purified form, analyzed by HPLC-DAD or HPLC-ELSD and identified by mass spectrometry and NMR.
Standardised extract capsules: At least one Phase I clinical trial has evaluated capsule-form standardised extract of a related Atractylodes species, indicating that encapsulated formulations of the herb are under clinical investigation, although specifically for atractylodin rather than isolated atractylone.

2. Traditional and Historical Use

Documentation in Classical Texts

Atractylodes macrocephala rhizome — called Baizhu in TCM — is a well-known herbal medicine that was documented in the earliest existing book on TCM, "Shen Nong's Materia Medica" (Shennong Bencao Jing), written during the Han Dynasty (A.D. 25–220). This places the herbal tradition surrounding this plant at nearly two millennia of continuous recorded use.

Ancient Chinese medicine treatises on Atractylodis Macrocephalae Rhizoma indicated that it possessed an expectorant effect; however, in modern times, it is commonly used as a tocolytic agent. This documented shift in application over time highlights how TCM's practical use of the plant evolved as empirical knowledge accumulated.

Traditional Uses in East Asia

Atractylodes macrocephala has gained prominence in traditional Chinese medicine for its purported health benefits, particularly its ability to tonify the spleen and stomach, regulate the flow of Qi (vital energy), and promote digestive health. Atractylodes, mainly Atractylodes macrocephala and Atractylodes lancea, has a long history in TCM as a "tonifying" herb; known as "Bai Zhu" in TCM, it was historically used to support digestive health, boost energy, reduce dampness (edema and bloating), and strengthen the immune system.

The rhizome has been traditionally used for the treatment of various disorders, such as loss of appetite, diarrhea, limb weakness, gastrointestinal dysfunction, and immune dysfunction. In TCM theory, these applications are framed within the concept of tonifying the "Spleen" organ system, which governs digestion, fluid metabolism, and the production of vital energy (Qi) from food.

In Mandarin, atractylodes is called Bai Zhu, Bai Shu, Yu Zhu, and Dong Zhu; the Cantonese term is Paak Sat, and the Japanese call it Byakujutsu; common names include large-headed atractylodes, white atractylodes, and white shu; its pharmaceutical name, used to distinguish it as a medicine, is Rhizoma Atractylodis, and it is one of more than 500 plants recognized as official drugs in TCM.

The effects of atractylon on the liver, kidney, spleen, and lung have been recorded in the classical pharmacopoeia of China. The plant was also used in Japanese Kampo medicine (as Byakujutsu) and in Korean traditional medicine, reflecting its integration across East Asian medical traditions.

The volatile oil fraction of the rhizome — which is the primary locus of atractylone — has specific traditional significance. Expectorant experiments indicated that the volatile oil fraction, which mainly contains atractylone, produced an obvious expectorant effect. This provides a pharmacological basis for the plant's classical description as an expectorant agent.

Atractylodes is commonly prescribed in conjunction with moisture-removing drugs and digestants; practitioners of Chinese medicine commonly also combine atractylodes with other Chinese herbs. A common classical formula pairs the rhizome with Radix codonopsis (Codonopsis pilosula, Dang Shen) and Rhizoma zingiberis (dried ginger root) for abdominal pain, distention, vomiting, and diarrhea.

It has been applied clinically for recuperation after surgery or chronic diseases with symptoms such as exhaustion, fatigue, pale face, diarrhea, loss of appetite, vomiting, and anorexia, especially for patients having digestive disorder; largehead atractylodes rhizome is also used for the treatments of carcinoma.

3. Key Constituents and Established Mechanisms of Action

Position Within the Phytochemical Context

Atractylone, a bioactive sesquiterpenoid, has been noted to exhibit numerous pharmacological effects, including cytotoxic, antimicrobial, anti-inflammatory, antiviral, anticancer, antioxidant, neuroprotective, and gastroprotective activities. It is important to note that the parent plant contains numerous co-occurring sesquiterpenes — particularly the atractylenolide lactones (AT-I, AT-II, AT-III) — whose pharmacology partially overlaps with and is sometimes conflated with atractylone's own activity in the literature. Atractylone is the predominant volatile sesquiterpene in the essential oil fraction, while the atractylenolides are more abundant in the non-volatile extract fractions.

Anti-inflammatory Mechanisms

The anti-microbial and anti-inflammatory activities of the constituents from Atractylodes rhizomes have been evaluated; atractylone showed anti-microbial activity, and atractylone and atractylenolide I possessed considerable anti-inflammatory activity utilizing the rat cotton pellet granuloma bioassay.

At the molecular level, atractylone can significantly inhibit nitric oxide (NO) and prostaglandin E2 (PGE2) production as well as the expression of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) in lipopolysaccharide-induced RAW 264.7 macrophage cells. This inhibition of the two primary enzymatic drivers of the inflammatory cascade — iNOS and COX-2 — is a well-characterised and mechanistically significant anti-inflammatory action.

Atractylone can both decrease the levels of tumor necrosis factor (TNF)-α and reactive oxygen species (ROS) and increase the expression of adhesion proteins such as claudin, ZO-1, and occludin in vitro, demonstrating combined anti-inflammatory and epithelial barrier-protective mechanisms. These tight-junction proteins are critical for maintaining intestinal epithelial integrity.

Antiviral Mechanisms

Atractylone has demonstrated significant antiviral activity by attenuating lung injury caused by influenza A virus (IAV) and regulating the TLR7 signaling pathway, as well as decreasing serum IL-6, TNF-α, and IL-1β levels and increasing IFN-β levels. The modulation of the TLR7 pathway is mechanistically important because TLR7 is a pattern recognition receptor that detects single-stranded viral RNA and triggers interferon-based antiviral responses.

In experiments on SARS-CoV-2-infected Vero E6 cells, it was demonstrated that atractylone could lower the levels of several key cytokines (IL-6, CCL-2, TNF-α, CCL-3, and CXCL-10) in a concentration-dependent manner. This cytokine-suppressive profile is of interest given the pathological role of cytokine storms in severe viral disease, though this evidence remains at the in vitro stage.

Anticancer Mechanisms

With further research on the chemical constituents and pharmacology of sesquiterpenes, research on the antitumor activity of atractylone has been further expanded; much of the current literature pays particular attention to the antitumor activity of atractylone, which was found to inhibit tumor cells and prevent growth, invasion, and migration through different apoptosis pathways and signaling pathways.

In hepatocellular carcinoma (HCC) cells, several convergent mechanisms have been identified. Atractylone can significantly inhibit the expression of Bcl-2, promote the expression of Bax and Cleaved caspase-3, and inhibit migration to induce apoptosis in HCCs. This Bcl-2/Bax axis is one of the canonical mitochondrial apoptosis pathways. Atractylone was also responsible for inhibiting the migration and invasion of HCCs by upregulating epithelial markers (E-cadherin), preventing epithelial–mesenchymal transformation (EMT), and reducing the expression of matrix metalloproteinase MMP.

At the transcriptomic level, by comparing transcriptome sequencing results of the atractylone treatment and control groups, 39 upregulated mRNAs, 39 downregulated mRNAs, 20 upregulated long non-coding RNAs and 21 downregulated lncRNAs were identified and screened. Among these, atractylone can regulate the expression of long-chain noncoding RNA TMPO-AS1 and lncRNA CCDC183-AS1; TMPO-AS1 was upregulated in HCC tissues and cells, and its depletion inhibited the proliferation and invasion of HCCs in vitro, as well as tumor growth and metastasis in vivo, making both TMPO-AS1 and CCDC183-AS1 potential targets for the diagnosis and treatment of liver cancer.

Current studies have found that the potential antitumor targets of atractylone include AKT, MMP-9, Bcl-xl, dipeptidyl peptidase IV, retinoic acid β receptor, and cellular retinoic acid binding protein 2, as well as TMPO-AS1 and CCDC183-AS1.

Regarding multidrug resistance in HCC, atractylone was explored for its action on chemotherapy resistance of HCCs based on the Notch 1 pathway; it was discovered that atractylone downregulated the expression of Notch1, Hes1, Jagged1, and Bcl-2, and upregulated the expression of Bax, promoting apoptosis.

Atractylon and atractylenolide I were identified as the major cytotoxic principle constituents of Atractylodes rhizome on leukemia cell lines.

Neuroprotective Mechanisms

Atractylone has been shown to activate DRD2 (the dopamine D2 receptor), attenuate motor deficits and gait disturbances, and protect dopaminergic neurons in Parkinson's disease mice, demonstrating its potential as a neuroprotective agent.

Atractylone treatment increased eGFP expression in a dose-dependent manner in a piggyBac-TANGO assay, decreased cAMP production, and enhanced the levels of phosphorylated CREB (p-CREB) and brain-derived neurotrophic factor (BDNF) in DRD2-highly-expressed SH-SY5Y cells. This profile — reducing cAMP while elevating BDNF — is consistent with neuroprotective D2 receptor agonism.

Antiallergic Mechanisms

Atractylone has inhibitory effects on mast cell-mediated allergic reactions; it regulates the degranulation of mast cells, proving its potential in the treatment of mast cell-mediated allergic reactions. Further study showed that atractylone could also inhibit tryptase and histamine releases in PMA/calcium ionophore A23187-induced HMC-1 cells; atractylone could inhibit morphological alteration and filamentous actin formation in stem cell factor-stimulated mast cells.

Biosynthetic Pathways

The biosynthesis of atractylone relies on two central terpenoid pathways: the mevalonate (MVA) pathway and the methylerythritol phosphate (MEP) pathway, reflecting the metabolic flexibility of plants in producing this compound.

4. Scientific Evidence by Area of Use

4.1 Anti-inflammatory Activity

Preclinical evidence (in vitro and in vivo): Atractylone can significantly inhibit NO and PGE2 production as well as the expression of iNOS and COX-2 in LPS-induced RAW 264.7 cells; furthermore, atractylone (40 mg/kg) significantly reduced the acetic-acid-induced writhing response, carrageenan-induced paw edema, and hot-plate latent pain response in mice. These are standard preclinical models of acute inflammation and nociception.

In the context of ulcerative colitis (UC), the aim of one study was to screen potential therapeutic compounds found in Atractylodes macrocephala rhizoma essential oil and explore its mechanism of action in the treatment of UC; an inflammation cell model was employed in conjunction with phospho-antibody array technology, and the DSS-induced colitis mouse model was also used — through this screening process, atractylone was identified as the primary active compound.

Evidence strength: Evidence for anti-inflammatory activity is primarily preclinical (cell culture and rodent models). No human clinical trials have specifically examined isolated atractylone for inflammatory conditions. Evidence is promising but preliminary.

4.2 Antiviral Activity

Preclinical evidence: Atractylone alleviates influenza A virus (IAV)-induced lung injury via regulating the TLR7 signaling pathway and acts as a promising agent for IAV treatment. A study reported in Molecular Medicine Reports (2016) documented antiviral activities of atractylone from Atractylodis Rhizoma against influenza. Pharmacodynamic results revealed that the essential oils of stir-fried atractylodes and atractylone exhibited more effective anticancer activity in HepG2, MCG803, and HCT-116 cells than the essential oils of bran-fried atractylodes; while the essential oils of bran-fried atractylodes exhibited simple antiviral effect on H3N2, both the essential oils and atractylone showed anti-inflammatory activity by inhibiting LPS-induced nitric oxide production in ANA-1 cells.

Regarding SARS-CoV-2, in experiments on SARS-CoV-2-infected Vero E6 cells, it was demonstrated that atractylone could lower the levels of several key cytokines (IL-6, CCL-2, TNF-α, CCL-3, and CXCL-10) in a concentration-dependent manner. This is an in vitro cell culture study only.

Evidence strength: All antiviral evidence is from in vitro experiments and animal models. No human clinical trials have tested atractylone against any virus. Evidence is preliminary and mechanistically suggestive only.

4.3 Anticancer Activity

Hepatocellular carcinoma (HCC): Multiple in vitro and in vivo studies have examined atractylone's effects in liver cancer models. Atractylone can significantly inhibit the expression of Bcl-2, promote the expression of Bax and Cleaved caspase-3, and inhibit migration to induce apoptosis in HCCs; the inhibitory effect of atractylone on HCCs may also be related to abnormal cell cycle regulation, and the intensity of action was obviously dose-dependent.

Previous studies reported that atractylone exhibits anti-oxidation, anti-bacterial, hypoglycemic, and antitumor effects; high-throughput sequencing was used to examine the molecular mechanisms underlying the inhibitory effect of atractylone on the invasion and migration of hepatic carcinoma cells.

Leukemia: Atractylenolide I has been reported to induce apoptosis and bring about cytotoxicity of human promyeloleukemic HL-60 cells; atractylon and atractylenolide I were the major cytotoxic principle constituents of Atractylodes rhizome on leukemia cell lines.

Gastric and colorectal cancer: Atractylone inhibited the proliferation of HepG2 and HCT-116 cells with lower IC₅₀ values than the essential oils from the tested atractylodes preparations; it is speculated that atractylone has strong antitumor activity in HepG2 and HCT-116 cells.

Clinical evidence: One randomised pilot study examined an Atractylodes extract (containing atractylenolide I as the named active compound) in gastric cancer cachexia patients, but this study measured clinical endpoints related to weight and quality of life rather than tumour response, and it examined the broad plant extract rather than isolated atractylone. Atractylenolides appear to be safe and reliable candidate anticancer agents in preclinical models, exhibiting potent antitumor efficacy both as monotherapy and in combination regimens; preliminary clinical data from a small pilot study indicated no signs of toxicity, but more extensive trials are needed to confirm their safety profile in humans. This caveat applies by extension to atractylone, for which no dedicated clinical cancer trial has been conducted.

Evidence strength: Anticancer evidence for atractylone is exclusively preclinical (cell lines and animal models). As a natural drug source, atractylone has a potential inhibitory effect on diverse cancers, including leukemia, and its comprehensive toxicity risk profile presents no obvious adverse reactions; its low toxicity, high content, and multi-efficacy make it one of the most promising natural anticancer drugs. However, no clinical trials in humans have been completed for isolated atractylone. Evidence is early-stage.

4.4 Neuroprotective Effects and Parkinson's Disease

Preclinical evidence: The most detailed neuroprotection study on atractylone examined its role as a dopamine D2 receptor (DRD2) agonist in Parkinson's disease models. Motor symptoms of Parkinson's disease are characterized by bradykinesia, resting tremor, rigidity, slow movement, impaired gait and postural instability, resulting from progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc).

Atractylone treatment increased eGFP expression in a dose-dependent manner in a piggyBac-TANGO assay, decreased cAMP production, and enhanced the levels of p-CREB and BDNF in DRD2-highly-expressed SH-SY5Y cells; in MPTP-induced mice, atractylone improved slow movement, diminished voluntary locomotion, and improved abnormal gait parameters such as duration, cadence, average speed, step cycle, and stride length; moreover, atractylone rescued tyrosine hydroxylase-positive cells in the SNpc and TH-positive nerve fibers in the striatum; the conclusion was that atractylone could effectively activate DRD2, attenuate motor deficits and gait disorders, and protect dopaminergic neurons in MPTP-induced PD mice.

In summary, one study revealed that atractylone could activate DRD2, reduce cAMP production, and elevate p-CREB and BDNF in vitro. This mechanism is consistent with the broader neuroprotective literature on DRD2 agonism in the context of neuroinflammation and dopaminergic neuron survival.

Evidence strength: Evidence is confined to in vitro cell assays and a preclinical MPTP mouse model. No clinical trials have been conducted. The DRD2 agonism mechanism is pharmacologically plausible and coherent with known neuroscience, but translation to humans remains unproven.

4.5 Gastroprotective and Gastrointestinal Effects

Atractylodes is slightly aromatic, relieves painful digestion, and is stimulating and diuretic; it improves digestion and counteracts fatigue and loss of appetite; the dried rhizome is used to tonify the spleen and to treat diarrhea and stomach problems. These are traditional descriptions corroborated to some degree by modern pharmacology.

Modern pharmacological researchers have confirmed that largehead atractylodes rhizome is effective in promoting gastrointestinal motility and intestinal secretion.

In the ulcerative colitis context, atractylone was identified as the primary active compound in the Atractylodes macrocephala rhizoma essential oil in a mechanistic screening study. Its protective mechanisms included restoring epithelial tight junction protein expression (claudin, ZO-1, occludin) and reducing pro-inflammatory cytokines.

Evidence strength: The gastroprotective and motility-promoting effects of Atractylodes rhizome are better established clinically than effects of isolated atractylone. While clinical trials in humans are limited, some studies suggest that Atractylodes may help improve digestive function, particularly in individuals with gastrointestinal disturbances. Evidence for isolated atractylone specifically in gastrointestinal disease is preclinical only.

4.6 Antiallergic Activity

Atractylone inhibits the degranulation of mast cells and exhibits potential for the treatment of mast cell-mediated allergic reactions. This has been demonstrated through cell-based assays using human mast cell lines (HMC-1) and rat peritoneal mast cells (RPMCs), with mechanisms involving suppression of tryptase, histamine release, and cytoskeletal reorganisation that drives degranulation.

Evidence strength: In vitro and animal-model evidence only. No human studies.

4.7 Antioxidant Activity

Atractylone exhibits a wide range of pharmacological effects, including anti-inflammatory, antiallergic, antiviral, antioxidant, and neuroprotective activities. Antioxidant properties have been demonstrated in cell-based assays, including suppression of reactive oxygen species (ROS) generation. However, antioxidant activity is consistently reported as a secondary or associated finding in studies primarily focused on other pharmacological endpoints rather than as a primary research focus in isolation.

Evidence strength: Preliminary, in vitro only.

5. Body Systems and Health Areas Associated with Atractylone

Previous investigations have reported multiple pharmacological properties for atractylone, including antiviral, anti-inflammatory, anticancer, hepatoprotective, neuroprotective, and gastroprotective effects. Based on the cumulative body of preclinical literature, the following organ systems have been studied:

Gastrointestinal system: Ulcerative colitis, gastric motility, appetite regulation, intestinal epithelial barrier integrity.
Hepatic system: Hepatocellular carcinoma models; hepatoprotective activity has been a focus since early studies in the 1980s (Kiso et al., Planta Med., 1985) that characterised the "mechanism of anti-hepatotoxic activity of atractylone."
Central nervous system: Parkinson's disease model (dopaminergic neuroprotection via DRD2 agonism); neuroinflammation.
Immune system: Innate immune modulation; mast cell degranulation; macrophage cytokine regulation; antiviral interferon pathway modulation (TLR7).
Respiratory system: Traditional expectorant use; IAV-induced lung injury protection in mouse models; cytokine modulation in SARS-CoV-2 in vitro models.
Oncology: Hepatocellular carcinoma, leukemia, colorectal cancer, gastric cancer — all preclinical.

6. Dosage Forms and Reported Dosages

The following dosages have been reported in source literature. It must be noted that no clinical dosage for isolated atractylone in humans has been established through clinical trials. All dosages for pure atractylone are from preclinical (animal or cell) studies unless otherwise specified.

Traditional rhizome decoction (human, traditional practice): The standard dose is 3–10 g as a decoction (strong tea) or 1–4 ml of tincture; doses of dried material are 3–12 g. These doses refer to the crude plant material, not isolated atractylone.
Anti-inflammatory (in vivo, mouse): Atractylone at 40 mg/kg significantly reduced the acetic-acid-induced writhing response, carrageenan-induced paw edema, and hot-plate latent pain response in mice.
Parkinson's disease model (in vivo, MPTP mice): Doses used in the DRD2 agonism/neuroprotection study in MPTP-induced mice were reported in the published literature (Li et al., 2022, Neurotoxicology), though specific mg/kg values from the original paper were not reproduced in the accessible secondary sources; the study confirmed dose-dependent effects.
Standardised extract capsule (Phase I human clinical trial — note: this refers to an Atractylodes lancea extract and specifically concerns atractylodin, not atractylone): A single oral dose of 1,000 mg of capsule formulation of the standardised Atractylodes lancea extract (each dose equivalent to 2.45 mg atractylodin) and daily oral doses of 1,000 mg for 21 days were evaluated. This is included to contextualise the clinical pharmacology of related compounds from the same plant genus, not as a dosage for isolated atractylone.

7. Pharmacokinetics

Pharmacokinetic studies suggest that atractylone exhibits efficient intestinal absorption, favorable bioavailability, and adequate metabolic stability, reinforcing its potential for therapeutic development. These findings derive from preclinical ADME (absorption, distribution, metabolism, excretion) studies; detailed human pharmacokinetic data for isolated atractylone are not available in the peer-reviewed literature.

These findings support the idea that atractylone could be considered an interesting candidate for pharmaceutical and cosmetic applications; nevertheless, the current body of evidence remains relatively limited, and several gaps persist, particularly regarding its pharmacodynamics, safety margins, and toxicity thresholds.

Detailed studies are needed to understand the absorption, distribution, metabolism, and excretion (ADME) profile of atractylone. The most detailed pharmacokinetic observations from the related compound atractylodin (from a Phase I clinical trial in humans using Atractylodes lancea extract) found that oral absorption was rapid but highly variable. Oral absorption of atractylodin was rapid but variable, with the observed t_max and C_max ranging from 0.5 to 2 h and 7.1–152.7 ng/ml, respectively; atractylodin was cleared in plasma of most participants within 4 h of administration; the systemic bioavailability reflected by AUC_0-∞ was relatively low due to rapid systemic clearance (CL/F: 2.87–14.82 l/kg/h) and large apparent volume of distribution (Vz/F: 3.58–31.55 l/kg). While atractylodin differs structurally from atractylone, both are lipophilic sesquiterpenoids from the same plant genus, and these data provide partial context for the likely behaviour of this compound class.

8. Safety Considerations and Interactions

General Toxicity Profile

As a natural drug source, atractylone has a potential inhibitory effect on diverse cancers, and its comprehensive toxicity risk profile presents no obvious adverse reactions. This assessment is based on preclinical evidence; comprehensive clinical toxicology data for isolated atractylone do not exist.

Comprehensive toxicology studies are required to establish a robust safety profile before any clinical consideration.

Stability-Related Considerations

The presence of double bonds in the skeleton of atractylone reduces its stability, making it unstable at room temperature and prone to self-oxidation under sunlight; the decrease in effective content caused by this instability greatly weakens its biological efficacy. This chemical instability has practical implications for storage, formulation, and the bioavailability of any preparation containing the compound.

Processing-Related Chemical Changes

In TCM, herbal medicines are in most cases uniquely processed; although it is thought that processing can alter the properties of herbal medicines so as to achieve desired functions, increase potency, and/or reduce side effects, the underlying chemical changes remain unclear for most thermally processed Chinese herbal medicines. Stir-frying with wheat bran — a common processing method for A. macrocephala rhizome — generates new atractylone-derived chemical entities whose pharmacological profiles differ from those of the parent compound. Biological activity evaluation showed that none of the newly generated thermally-induced compounds possessed cytotoxic effects against tested mammalian cancer and noncancer cell lines, and all compounds were ineffective at inhibiting the growth of pathogenic microorganisms, suggesting that thermal processing may reduce some bioactivities present in the raw extract.

Plant Allergies

Atractylodes should be used cautiously in pregnant or breastfeeding women and those with allergies to related plants, such as those in the Asteraceae family. This cross-reactivity concern is based on the botanical family-level relationship among Asteraceae species.

Drug Interactions

No well-documented, source-verified drug interaction data specific to isolated atractylone are available in the peer-reviewed literature. The compound's modulation of cytokine pathways (TNF-α, IL-6, NF-κB), DRD2 receptor signalling, and potential effects on hepatic metabolism are pharmacologically plausible interaction points requiring formal investigation. Several gaps persist in the current body of evidence, particularly regarding pharmacodynamics, safety margins, and toxicity thresholds.

Absence of Clinical Human Data

These activities are supported by a growing number of in vitro and in vivo studies, suggesting that atractylone may act through several interconnected molecular pathways; despite this promising profile, research on atractylone remains fragmented, and most available studies examine isolated biological activities without integrating its broader chemical and mechanistic context. The critical limitation of the entire atractylone evidence base is that, as of 2026, no published randomised controlled trials or Phase I/II clinical trials have evaluated isolated atractylone in human subjects for any indication. All pharmacological conclusions derive from cell culture systems or animal models, and translation to human therapeutic application has not been established.

References

Health Conditions

Health conditions that Atractylone may help support.

No conditions available.

Body Systems

Body systems that Atractylone may help support.

No body systems available.